Latest news with #LIFE
Cision Canada
14 hours ago
- Business
- Cision Canada
BIOVAXYS ANNOUNCES AMENDED LIFE OFFERING
VANCOUVER, BC, June 20, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (" BioVaxys" or the " Company") announces that it has amended the terms of its brokered private placement LIFE financing (the " Offering") previously announced on May 30, 2025, and filed an amended offering document (the " Amended Offering Document"). The Amended Offering Document updates the exercise price of the common share purchase warrant that forms part of the units (" Units") being offered by the Company from a post-consolidation exercise price of $0.60 to a post-consolidation exercise price of $0.50. As previously announced, the Company intends to consolidate the common shares of the Company (the " Common Shares") on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the " Consolidation"), and complete a concurrent Offering consisting of a minimum of 5,714,285 Units at a post-Consolidation price of $0.35 per Unit for minimum gross proceeds of $2,000,000 and a maximum of 8,571,428 Units at a post-Consolidation price of $0.35 per Unit for maximum gross proceeds of up to $3,000,000. Each Unit will consist of one (1) post-Consolidation common share in the capital of the Company (each, a " Post-Consolidation Common Share") and one (1) Post-Consolidation Common Share purchase warrant (each, a " Post-Consolidation Warrant"). Each Post-Consolidation Warrant will entitle the holder thereof to purchase one Post-Consolidation Common Share at a post-Consolidation price of $0.50 for a period of 36 months from the closing date of the Offering. Closing of the Offering is anticipated to occur on or about June 30, 2025, or such other date as the Company may agree upon provided such date is on or before July 14, 2025. Closing of the Offering is subject to the satisfaction of certain conditions, including, but not limited to, acceptance by the CSE. The Company intends to use the net proceeds raised from the Offering for research and development, general corporate purposes and working capital. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (" NI 45-106"), the Units issuable under the Offering will be offered for sale to purchasers in all provinces and territories of Canada, except Quebec, pursuant to the listed issuer financing exemption (" LIFE") under Part 5A of NI 45-106. The securities to be issued pursuant to the sale of the Units under the Offering will not be subject to resale restrictions in accordance with applicable Canadian securities laws. There is an Amended Offering Document dated June 18, 2025, related to the Offering that can be accessed under the Company's profile at and on the Company's website at Prospective investors should read this offering document before making an investment decision. This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit and connect with us on X and LinkedIn. ON BEHALF OF THE BOARD Signed " James Passin" James Passin, Chief Executive Officer Phone: +1 740 358 0555 Cautionary Statements on Forward Looking Information This news release includes certain "forward-looking information" and "forward-looking statements" (collectively " forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, the proposed Consolidation, including the ratio thereof and timing thereof, and the Offering, including the size and use of proceeds, and the timing and ability of the Company to close the Offering, including obtaining approval of the Offering from the CSE. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the ability of the Company to complete the Consolidation and the Offering on the terms proposed or at all, and the ability to obtain necessary approvals, including the approval of the CSE. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws.
Express Tribune
3 days ago
- Health
- Express Tribune
Adriana Smith's baby delivered by C-section after mother was declared brain-dead during pregnancy
Adriana Smith, the 30-year-old Georgia woman who was declared brain-dead earlier this year, was removed from life support on Tuesday after her baby was born via Caesarean section. The procedure took place on Friday evening at Emory University Hospital Midtown in Atlanta. The newborn, named Chance, weighed one pound, thirteen ounces and is currently being cared for in the neonatal intensive care unit. Smith's mother, April Newkirk, confirmed that her daughter was about six months pregnant when she was removed from life support. Her medical ordeal began after severe headaches led to a hospital visit, where she was treated and discharged without further testing. She was later admitted to Emory, where blood clots were found following a CT scan. Smith's case has drawn national attention amid Georgia's strict abortion laws, particularly the Living Infants Fairness and Equality (LIFE) Act. The legislation recognises fetal personhood, potentially complicating medical decisions after 'a detectable human heartbeat' is present which is possible as early as six weeks. Smith was nine weeks pregnant when she started experiencing symptoms . The case has reignited political and ethical debates around reproductive rights and medical care. U.S. Representative Nikema Williams is leading federal efforts to clarify patient rights and repeal restrictive state laws that interfere with end-of-life and reproductive care.
Agriland
13-06-2025
- Agriland
Report published on work of NPWS in 2024
A report detailing the work of the National Parks and Wildlife Service (NPWS) in 2024 has been published by the government. Among the notable highlights in the report is the increase of national parks from six to eight, including the establishment of Ireland's first marine national park, Páirc Náisiúnta na Mara Ciarraí in Co. Kerry. National parks in Ireland saw over 5.5 million visitors in 2024, according to the report. 2024 also saw the publication of Ireland's fourth National Biodiversity Action Plan, which is the first to be backed by legislation and legal requirements for public bodies to 'embed biodiversity and report their progress'. The report also said that protection of waters in Ireland increased from 2% to 9%, including the 'Seas off Wexford' Special Protected Area (SPA). The report noted that peatland habitat restoration measures were completed on an area of more than 565ha across eight protected raised bog sites under NPWS programmes. On the issue of 'wildlife crime', the report said that the NPWS enhanced collaboration with other enforcement agencies, including An Garda Síochána, with 30 new prosecution cases for alleged breaches of wildlife legislation. Throughout 2024, the NPWS continued to administer seven LIFE projects, including the LIFE 'integrated projects' (IPs) such as Wild Atlantic Nature and the Corncrake LIFE. The purpose of these projects, according to the NPWS, is to protect and restore Ireland's habitats and species. Other projects include Tochár Wetlands Restoration, and a new European Innovation Partnership (EIP) for breeding wader birds. Commenting on the NPWS report, Minister for Housing, Local Government and Heritage James Browne said: 'Notable achievements for the NPWS last year included the acquisition of land for nature; the expansion of national parks; rolling out a range of conservation projects; and strengthening partnerships with communities around the country.' 'This government is committed to continuing this work. 2025 sees record levels of investment in our natural heritage, including €78 million in core funding to the NPWS. 'I would like thank NPWS staff around the country for their exceptional work to protect our valuable natural heritage for all of us and future generations,' Minister Browne added. Also commenting on the report, Minister of State for Nature, Heritage and Biodiversity Christopher O'Sullivan said: 'Our National Parks and Nature Reserves are vital ecosystems which combat climate change, protect biodiversity and provide spaces for recreation, mental wellbeing and the enjoyment of Ireland's wild landscapes. 'Ensuring that the NPWS has the resources it needs to thrive is essential to safeguarding these spaces for the species which depend on them for survival, along with the 5.5 million people who visited and enjoyed Ireland's national parks last year,' Minister O' Sullivan added. Niall Ó Donnchú, Director General of the NPWS, said: 'A wide range of NPWS initiatives, projects and funding streams are now delivering positive change for nature. 'Partnership with communities, farmers and landowners has been key, and I would like to pay tribute to them for their ongoing collaboration,' Ó Donnchú.
Time Out Dubai
12-06-2025
- Entertainment
- Time Out Dubai
Ready for a dramatic dinner this summer? Head to The Theater
If you're after the very best dinner show in Dubai – one that fuses world-class entertainment with jaw-dropping dining – The Theater is the only name you need to know. Expect music that gives you goosebumps, performances that hit you right in the heart and a vibe that's pure electricity from the second the curtain lifts. A night at The Theater is anything but ordinary. And this summer, things get even more extraordinary as LIFE, a show about the trials and tribulations of life, returns to the stage with a bang. It's bold. It's beautiful. It's a little bit wild. And frankly, it could be the most fun you'll have all summer. Directed by the brilliant Maestro Guy Manoukian and choreographed by the powerhouse Maria Khomenko, the production takes you on an emotional rollercoaster. Told through explosive live music, breathtaking dance and cinematic stage decor, LIFE aims to consume you into its heart-wrenching story of love, resilience, desire and triumph. As Manoukian puts it, 'Life is about connection. It's real, raw and emotionally charged, we want every guest to feel something unforgettable.' And you absolutely do. Of course, it wouldn't be a night out without top-tier food, and The Theater's culinary experience is as standout as the show. The menu is a gorgeous blend of Mediterranean soul and Japanese finesse. The dishes are exquisitely plated, desserts are showstopping and drinks are clearly well thought of. After the performance, the space comes alive with high nightlife energy, complete with DJ sets and elevated party ambience. Life at The Theater runs all summer long, with performances every Thursday, Friday, and Saturday night. Whether you're hosting out-of-towners or having a special date night, this is the kind of place that makes a night unforgettable. Go on and experience LIFE. Book now: 04 222 2268, 056 996 4664 Book online: To know more: Fairmont Dubai, Sheikh Zayed Road, (04 222 2268).
The Hindu
11-06-2025
- Business
- The Hindu
Thiruvananthapuram Corporation retakes possession of unoccupied and rented out welfare scheme flats
The Thiruvananthapuram Corporation has begun the process of retaking possession of flats built for economically backward families which have either been rented out to third parties or have remained unoccupied even years after they were handed over to beneficiaries. According to officials in the Corporation's housing wing, 15 flats have been taken over until now and reallocated to families identified as landless and homeless under the State government's project to uplift extremely poor families. Last week, it was to one such unoccupied flat that the Corporation had retaken possession of that the authorities shifted a four-member family found to be living in a dilapidated one room shed at Muttathara. Survey and follow-up action Officials said the Corporation had an year ago begun a survey to check whether the flats which were provided under various schemes for economically backward families are being occupied by the original beneficiaries to whom they were provided. As many as 60 flats were found to be either vacant or rented out to third parties. These were mainly in the residential complex built over a decade ago under the Basic Services for Urban Poor (BSUP) project at Kalladimukham and another under the same project which was completed more recently at Poonkulam. According to the officials, one of the reasons for some of the original beneficiaries not occupying these flats built under the old housing scheme could probably be its smaller size. These are one BHK apartments of 320 square feet area. Over the past year, the Corporation had served three notices to the beneficiaries. Following the notices, a few families had returned to their flats to stay. The Corporation has taken possession of the rest of the flats. As many as 50 families in the Corporation identified as extremely poor are landless and homeless. Of them, 15 have now been provided flats by retaking possession from the original beneficiaries. The Corporation has been struggling to find adequate land in accessible areas to build residential complexes under the LIFE project too. This could partly explain the closer scrutiny of flats already awarded to beneficiaries.
